OR WAIT null SECS
This episode features a discussion on a pair of AID system integrations with the Dexcom G7 CGM system as well as important updates in the diabetes technology portion from the ADA's Standards of Care—2024.
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss the latest in diabetes technology from December 2023, with a spotlight on announcements surround use of Dexcom’s G7 continuous glucose monitoring (CGM) system as well as the latest updates to the American Diabetes Association’s Standards of Care.
The first half of December 2023 featured a month of December featured a pair of announcements from Tandem Diabetes Care, Inc. and Beta Bionics, Inc.
On December 06, 2023, Tandem Diabetes Care announced the launch of updated t:slim X2 insulin pump software with Dexcom G7 CGM integration in the US. At the time of the announcement, the move made the t:slim X2 pump the first AID option in the world able to use Dexcom’s latest CGM technology.1
On December 07, 2023, Beta Bionic, Inc. announced the nationwide launch of a firmware update allowing users to update their iLet Bionic Pancreas automated insulin delivery system with the Dexcom G7 CGM system without any additional cost for new hardware. To use the upgrade, existing iLet Bionic Pancreas users can download or update the iLet app from the Apple App store or Google Play store beginning on December 18, 2023 and, once they have updated their iLet app, can update the firmware on their iLet Bionic Pancreas.2
Unlike many professional organizations, the American Diabetes Association provides an annual update on best practices for management. A reflection of the field’s growing interest in optimizing use of diabetes technology, the Standards of Care in Diabetes—2024 features more than half a dozen changes to the section on diabetes technology compared to the 2023 iteration.3
Notable recommendation changes are highlighted below:3
Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.